ESMO Advanced Course on EGFR Exon 20 Insertion Mutations in NSCLC: Optimising Patient Diagnosis and Management

- Start date
- 05 Dec 2022
- End date
- 06 Dec 2022
- Location
- Singapore, Republic of Singapore
Learning objectives
- To understand the function and biology of EGFR and exon 20 insertion mutations in normal and malignant lung epithelial cells
- To gain insights in the spectrum of atypical EGFR molecular aberrations, platforms and strategies for molecular testing
- To provide information and in-depth discussion on the state-of-the-art and emerging therapeutic strategies integrating EGFR exon 20 insertion mutation inhibition in non-small-cell lung cancer
- To present novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of EGFR exon 20 mutation inhibition
Accreditation
The programme of this event has been accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- Sanjay Popat, United Kingdom
- Ross A. Soo, Singapore